The Clinical Investigation of Pemetrexed Plus Carboplatin as an Active and Tolerable Treatment Plan in Chinese Elderly Patients with Advanced Lung Adenocarcinoma

Yu-Quan Wu, Jun Yang, Xi-Jian Zhou, Peng Li, Xiao-Qiang Fan, Guang-Zhou Lu, Yan-Juan Pan, Xiang-Yong Li, Fu-Lin Yan

.
College of Pharmacy, Xinxiang Medical University, Xinxiang, Henan 453003, China.

DOI: 10.4236/jct.2011.23042                

Abstract

The standard chemotherapy for Chinese elderly patients with non-small cell lung cancer (NSCLC) remains undefined. The study was to evaluate the therapeutic effects as well as side effects of pemetrexed plus carboplatin regimen as the first-line therapy for Chinese elderly patients with advanced lung adenocarcinoma. Twenty-three Chinese elderly patients (male 14 and female 9, average age 73.7 years, range 70~81 years) with advanced lung adenocarcinoma received pemetrexed plus carboplatin as the first-line therapy, in detail, pemetrexed 500 mg/m2 and carboplatin AUC 5 mg/ml/m2 were given intravenously on day 1. The treatment was repeated everyday in the 21 days cycle. Therapeutic effects were evaluated at least after two cycles of treatment. The remission rate, disease control rate, time to progression and overall survival were observed. The results showed that all the cases were valid for response evaluation, with the complete remission 0 case, partial remission 8 cases, stabilize disease 9 cases and progression disease 6 cases. The remission rate (including complete remission and partial remission) was 34.8%, disease control rate 73.9%, the time to progression was 5.8 months and the overall survival 13.7 months. There showed the positive relationship between the curative effects (either time to progression or overall survival) and chemotherapy cycles. The main toxicities were bone marrow suppression, nausea and vomiting. There was no chemotherapy-related death. The data suggested that the combination regimen with pemetrexed plus carboplatin is an active and tolerable treatment plan for Chinese elderly patients with advanced lung adenocarcinoma, in which the side effects were tolerable and manageable.

Keywords

Pemetrexed, Carboplatin, Chinese Elderly Patient, Lung Adenocarcinoma

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	X. Q. Liu and L. L. Qu, “The Clinical Characteristic, Current Therapeutic Situation and Tendency of Non- Small-Cell Lung Carcinoma in Advanced Stage,” Chinese Oncology Clinical Album, 2007, pp. 184-189.
[2]	M. Duruisseaux, J. Cadranel, E. Biron, M. Pérol, J. C. Guérin and D. Arpin, “Major and Prolonged Response to Pemetrexed in Two Cases of Lung Adenocarcinoma with Bronchioloalveolar Carcinoma Features,” Lung Cancer, Vol. 65. No. 3, 2009, pp. 385-387. doi:10.1016/j.lungcan.2009.02.018
[3]	M. Duruisseaux, J. Cadranel, M. Pérol and D. Arpin, “The Role of Pemetrexed in Lung Adenocarcinoma, Mixed Subtype with Bronchioloalveolar Carcinoma Features,” Current Drug Targets, Vol. 11, 2010, pp. 74-77. doi:10.2174/138945010790031045
[4]	T. Sasaki, H. Yasuda, K. Nakayama, M. Asada, S. Okinaga, T. Suzuki, et al., “Pleurodesis with Carboplatin in Elderly Patients with Malignant Pleural Effusion and Lung Adenocarcinoma,” Journal of the American Geriatrics Society, Vol. 54, No. 4, 2006, pp. 722-723. doi:10.1111/j.1532-5415.2006.00668_9.x
[5]	W. D. Travis, E. Brambilla, M. Noguchi, A. G. Nicholson, K. R. Geisinger, Y. Yatabe, et al., “International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma,” Journal of Thoracic Oncology, Vol. 6, No. 2, 2011, pp. 244-285. doi:10.1097/JTO.0b013e318206a221
[6]	L. Crinò, F. Cappuzzo, P. Zatloukal, M. Reck, M. Pesek, J. C. Thompson, et al., “Gefitinib versus Vinorelbine in Chemotherapy-Naive Elderly Patients with Advanced Non-Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study,” Journal of Clinical Oncology, Vol. 26, No. 26, 2008, pp. 4253-4260.
[7]	G. Sartori, A. Cavazza, A. Sgambato, A. Marchioni, F. Barbieri, L. Longo, et al., “EGFR and K-ras Mutations along the Spectrum of Pulmonary Epithelial Tumors of the Lung and Elaboration of a Combined Clinicopathologic and Molecular Scoring System to Predict Clinical Responsiveness to EGFR Inhibitors,” Journal of Clinical Pathology, Vol. 131, 2009, pp. 478-489. doi:10.1309/AJCPH0TRMPXVZW2F
[8]	P. Wheatley-Price, K. Ding, L. Seymour, G. M. Clark and F. A. Shepherd, “Erlotinib for Advanced Non-Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21,” Journal of Clinical Oncology, Vol. 26, No. 4, 2008, pp. 2350-2357. doi:10.1200/JCO.2007.15.2280
[9]	J. D. Patel, T. A. Hensing, A. Rademaker, E. M. Hart, M. G. Blum, D. T. Milton, et al., “Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab with Maintenance Pemetrexed and Bevacizumab as First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 27, No. 20, 2009, pp. 3284-3289. doi:10.1200/JCO.2008.20.8181
[10]	H. Yasuda, K. Nakayama, M. Watanabe, S. Suzuki, H. Fuji, S. Okinaga, et al., “Nitroglycerin Treatment may Enhance Chemosensitivity to Docetaxel and Carboplatin in Patients with Lung Adenocarcinoma,” Clinical Cancer Research, Vol. 12, 2006, pp. 6748-6757. doi:10.1158/1078-0432.CCR-06-1124
[11]	L. Balducci, C. L. Hardy and G. H. Lyman, “Hemopoietic Reserve in the Older Cancer Patient: Clinical and Economic Considerations,” Cancer Control, Vol. 7, No. 6, 2000, pp. 539-547.
[12]	Elderly Lung Cancer Vinorelbine Italian Study Group. “Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients with Advanced Non-Small-Cell Lung Cancer,” Journal of National Cancer Institution, Vol. 91, No. 1, 1999, pp. 66-72. doi:10.1093/jnci/91.1.66
[13]	C. Gridelli, F. Perrone, C. Gallo, S. Cigolari, A. Rossi, F. Piantedosi, et al., “Chemotherapy for Elderly Patients with Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial,” Journal of National Cancer Institution, Vol. 95, No. 5, 2003, pp. 362-372. doi:10.1093/jnci/95.5.362
[14]	K. Takeda, T. Hida, T. Sato, M. Ando, T. Seto, M. Satouchi, et al., “Randomized phase III Trial of Platinum- Doublet Chemotherapy Followed by Gefitinib Compared with Continued Platinum-Doublet Chemotherapy in Japanese Patients with Advanced Non-Small-Cell Lung Cancer: Results of a West Japan Thoracic Oncology Group Trial (WJTOG0203),” Journal of Clinical Oncology, Vol. 28, No. 5, 2010, pp. 753-760. doi:10.1200/JCO.2009.23.3445
[15]	N. Hanna, F. A. Shepherd, F. V. Fossella, J. R. Pereira, F. De Marinis, J. von Pawel, et al., “Randomized Phase III Trial of Pemetrexed versus Docetaxel in Patients with Non–Small-Cell Lung Cancer Previously Treated with Chemotherapy,” Journal of Clinical Oncology, Vol. 22, No. 9, 2004, pp. 1589-1597. doi:10.1200/JCO.2004.08.163
[16]	S. Kudoh, K. Takeda, K. Nakagawa, M. Takada, N. Katakami, K. Matsui, et al., “Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients with Advanced Non-Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904),” Journal of Clinical Oncology, Vol. 24, No. 22, 2006, pp. 3657-3663. doi:10.1200/JCO.2006.06.1044
[17]	C. Delbaldo, S. Michiels, N. Syz, J. C. Soria, T. Le Chevalier and J. P. Pignon, “Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non-Small-Cell Lung Cancer a Meta-Analysis,” The Journal of American Medical Association, Vol. 292, 2004, pp. 470-484. doi:10.1001/jama.292.4.470
[18]	C. J. Langer, J. Manola, P. Bernardo, J. W. Kugler, P. Bonomi, D. Cella, et al., “Cisplatin-Based Therapy for Elderly Patients with Advanced Non-Small-Cell Lung Cancer: Implications of Eastern Cooperative Oncology Group 5592, a Randomized Trial,” Journal of National Cancer Institution, Vol. 94, 2002, pp. 173-181.
[19]	G. V. Scagliotti, P. Parikh, J. von Pawel, B. Biesma, J. Vansteenkiste, C. Manegold, et al., “Phase III Study Comparing Cisplatin Plus Gemcitabine with Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients with Advanced-Stage Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 26, No. 21, 2008, pp. 3543-3551. doi:10.1200/JCO.2007.15.0375
[20]	T. Ciuleanu, T. Brodowicz, C. Zielinski, J. H. Kim, M. Krzakowski, E. Laack, et al., “Maintenance Pemetrexed Plus Best Supportive Care versus Placebo Plus Best Supportive Care for Non-Small-Cell Lung Cancer: A Randomised, Double-Blind, Phase 3 Study,” Lancet, Vol. 371, 2009, pp. 1432-1440. doi:10.1016/S0140-6736(09)61497-5
[21]	F. Grossi, M. Aita, A. Follador, C. Defferrari, A. Brianti, G. Sinaccio, et al., “Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non- Small-Cell Lung Cancer: A Review of the Literature,” Oncologist, Vol. 12, No. 4, 2007, pp. 451-464. doi:10.1634/theoncologist.12-4-451